Staying upfront innovation
By investing in the future
At HTL Biotechnology, staying at the forefront of innovation is ingrained in our DNA. We are committed to continuously invest in our production, R&D, quality, capacities and innovation, ensuring that we remain at the cutting edge of technology.
By embracing the latest advancements and state-of-the-art practices, we aim to deliver high-quality and sustainable solutions.
Growing DNA production capacities
We are proactively expanding our production capabilities to meet the ever-increasing demand for PDRN/PN and Sodium DNA.
In 2023, we are set to achieve an impressive DNA capacity growth. By 2025, we are projected to achieve more than double our production capacity.
This capacity growth reflects our dedication to fulfilling the needs of our valued customers and partners.
A new GMP Chemistry lab
A new GMP chemistry lab was oppened in march 2023. This unit will be used to manufacture functionalized Hyaluronic Acids to meet the growing demand of our customers in our Functionalized Biopolymers Services.
This brand-new facility is equipped with state-of-the-art equipment thanks to several months of strong collaboration and involvement of the R&D, qualification and industrial performance teams.
A new production unit
HTL opened in 2021 a new bioproduction unit, HTL 4, in Javené, France, with a groundbreaking investment of 50 million euros.
Focusing on pharmaceutical-grade hyaluronic acid, the unit uses state-of-the-art automation to increase production capacity by a factor of 2.3, while ensuring exceptional product quality and significant environmental benefits, including a 50% reduction in water consumption per unit produced.
It offers also a double-sourcing for the customer and a security of supply.
A new Asian subsidiary
Following the creation of its US affiliates in 2021, HTL has established its Asian affiliate in December 2022.
This new affiliate signifies the company’s ongoing global expansion and dedication to serving healthcare customers across all Asian countries. Operating from Singapore, HTL Biotechnology Asia will bring the company closer to its clients and ensure an unparalleled support.
A new American production unit for Toxin
In 2021, HTL Biotechnology opened a new subsidiary, HTL Biotechnology Manufacturing Inc, which will focus on the production of Botulinum Toxin with a brand new production unit in the United States.